Baidu
map

Oncotarget:重磅!科学家鉴别出肝癌的天然抑制蛋白

2017-05-10 生物谷 生物谷

日前,一项刊登在国际杂志Oncotarget上的研究报告中,来自奥古斯塔大学的研究人员通过研究发现,一种能够帮助细胞进行有序组织并且完成任务的关键蛋白或许是预防肝癌的一种肿瘤抑制子。这种名为Scrib的蛋白质会根据癌症类型作为肿瘤抑制蛋白和癌基因而出现,在肝癌中该蛋白往往会从细胞的保护外层迁移进入细胞内部发挥作用,一旦进入细胞内部,该

日前,一项刊登在国际杂志Oncotarget上的研究报告中,来自奥古斯塔大学的研究人员通过研究发现,一种能够帮助细胞进行有序组织并且完成任务的关键蛋白或许是预防肝癌的一种肿瘤抑制子。这种名为Scrib的蛋白质会根据癌症类型作为肿瘤抑制蛋白和癌基因而出现,在肝癌中该蛋白往往会从细胞的保护外层迁移进入细胞内部发挥作用,一旦进入细胞内部,该蛋白的表达就会增加,同时还会抑制三种促进肝癌发生的癌基因进行表达。

图片摘自:Phil Jones

分子生物学家Satya Ande表示,这项研究中我们首次发现,在肝癌中,当细胞开始癌变时,Scrib蛋白能够转移到细胞质和细胞核中;Scrib能够作为肿瘤抑制蛋白尽力抑制癌细胞的生长。同时本文研究首次给出证据表明,在人类和动物的肝癌中Scrib能够充当肿瘤抑制蛋白的角色。

Scrib蛋白通常会驻留在细胞膜中来维持细胞极性;研究者Ande说道,在肝癌中我们发现有些Scrib蛋白会依然停留在细胞膜中,但有些Scrib蛋白却会移动到细胞质以及细胞核中,一旦该蛋白发生移动其就能够发挥作用来抑制Yap1, c-Myc和cyclin D1三种癌基因的表达。当仅对对Scrib蛋白进行重定位并且增加其表达并不会消除小鼠模型中的肿瘤时,研究者发现小鼠机体的肿瘤变小了,低水平的Scrib大白会增强动物模型中肝脏肿瘤的生长,但高水平的Scrib则能够抑制培养液中肝癌细胞的生长;而且研究者也并未在Scrib缺失的小鼠机体中发现自然发生的肝癌出现,这也就表明该蛋白在肝脏中并不扮演正常的角色。

更有意思的是,研究者还发现,在其它某些类型的癌症中,Scrib蛋白的运动以及其表达量的增加是其促进癌症发生的标志。下一步研究人员将通过更为深入的研究来阐明Scrib作为肝癌抑制蛋白的重要性,目前研究人员发现在30例所研究的人类肝脏肿瘤中,有70%的肿瘤中Scrib蛋白的表达都会增加,而在不同癌症中,该蛋白似乎扮演着不同的角色,比如,低水平的Scrib似乎能够减缓淋巴瘤发生的开端,但同时研究者在结肠癌、前列腺癌以及乳腺癌中也发现了低水平的Scrib蛋白,在这些癌症中,Scrib能够移动到细胞质中促进癌症发展,当然这至少是在动物模型中的研究结果。

最后研究者表示,Scrib蛋白似乎在大部分癌症中表达水平较高,后期我们还将通过更为深入的研究来阐明其在多种癌症中扮演的角色以及如何利用该蛋白开发治疗多种人类癌症的新型疗法。

原始出处:

Scrib protein identified as a natural suppressor of liver cancer

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1795360, encodeId=f71b1e95360ab, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon May 22 15:20:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197082, encodeId=454c19e08258, content=新发现,希望对临床有用,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri May 12 12:29:25 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549116, encodeId=c4c0154911681, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri May 12 01:20:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196458, encodeId=0cdf19645858, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。点赞啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:47:52 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196413, encodeId=2892196413ce, content=继续学习。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu May 11 06:11:59 CST 2017, time=2017-05-11, status=1, ipAttribution=)]
    2017-05-22 闆锋旦
  2. [GetPortalCommentsPageByObjectIdResponse(id=1795360, encodeId=f71b1e95360ab, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon May 22 15:20:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197082, encodeId=454c19e08258, content=新发现,希望对临床有用,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri May 12 12:29:25 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549116, encodeId=c4c0154911681, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri May 12 01:20:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196458, encodeId=0cdf19645858, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。点赞啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:47:52 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196413, encodeId=2892196413ce, content=继续学习。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu May 11 06:11:59 CST 2017, time=2017-05-11, status=1, ipAttribution=)]
    2017-05-12 luominglian113

    新发现,希望对临床有用,谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1795360, encodeId=f71b1e95360ab, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon May 22 15:20:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197082, encodeId=454c19e08258, content=新发现,希望对临床有用,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri May 12 12:29:25 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549116, encodeId=c4c0154911681, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri May 12 01:20:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196458, encodeId=0cdf19645858, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。点赞啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:47:52 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196413, encodeId=2892196413ce, content=继续学习。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu May 11 06:11:59 CST 2017, time=2017-05-11, status=1, ipAttribution=)]
    2017-05-12 xxxx1054
  4. [GetPortalCommentsPageByObjectIdResponse(id=1795360, encodeId=f71b1e95360ab, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon May 22 15:20:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197082, encodeId=454c19e08258, content=新发现,希望对临床有用,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri May 12 12:29:25 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549116, encodeId=c4c0154911681, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri May 12 01:20:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196458, encodeId=0cdf19645858, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。点赞啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:47:52 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196413, encodeId=2892196413ce, content=继续学习。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu May 11 06:11:59 CST 2017, time=2017-05-11, status=1, ipAttribution=)]
    2017-05-11 ylzr123

    认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。点赞啦!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1795360, encodeId=f71b1e95360ab, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon May 22 15:20:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197082, encodeId=454c19e08258, content=新发现,希望对临床有用,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri May 12 12:29:25 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549116, encodeId=c4c0154911681, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri May 12 01:20:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196458, encodeId=0cdf19645858, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。点赞啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:47:52 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196413, encodeId=2892196413ce, content=继续学习。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu May 11 06:11:59 CST 2017, time=2017-05-11, status=1, ipAttribution=)]
    2017-05-11 doctorJiangchao

    继续学习。

    0

相关资讯

JEM:抑制肝细胞c-Fos活性降低肝胆固醇减少癌变风险

研究人员,根据以往的肝癌细胞的基因组数据发现,在肝癌细胞线或者病人的肝癌细胞样本也观察到c-FOS和LXRα通路之间的成反相关。这些发现提供慢性炎症如何导致肝细胞代谢紊乱引起肝细胞癌变提供了分子机制。未来可能通过研制c-Fos的小分子抑制剂从而降低肝癌发生的疗法。

重磅!FDA今日批准近十年来肝癌药物regorafenib

今日,美国FDA传来重磅消息——拜耳(Bayer)药物Stivarga(regorafenib)获批扩大适应症,治疗那些已使用过肝癌药物sorafenib进行治疗,但疾病依旧出现进展的肝细胞癌患者。值得一提的是,这是美国FDA在近10年来批准的首款肝癌药物。肝细胞癌是最常见的肝癌类型。根据美国国家癌症研究所(NCI)的数据,全美今年将有约40710名新发肝癌患者,并有28290人将死于肝癌。作为一

J Clin Oncol:元云飞和李斌奎教授团队在肝癌分子标记物研究获得重要突破

元云飞和李斌奎教授团队在应用DNA 甲基化标记物预测早期肝癌复发研究取得了重要突破,相关研究成果2017年1月9日在线发表于国际顶级肿瘤学专业期刊《Journal of Clinical Oncology》(最新IF=20.98)。近年来,随着影像医学的进步和健康意识的提高,越来越多的早期肝癌被发现和诊断。早期肝癌手术切除后预后较好,但仍约有一半病人手术后会出现复发。传统临床病理因素无法用于预测早

Nat Commun:王红阳课题组等揭示与肝癌发生和转移相关的新型长链非编码RNA基因

近期,国际学术权威刊物自然出版集团旗下子刊《Nature Communications》杂志在线发表了清华大学生命科学学院鲁志课题组、信息学院与医学院张奇伟课题组以及上海东方肝胆医院王红阳院士课题组合作发表题为Recurrently deregulated lncRNAs in hepatocellular carcinoma的研究论文,论文通过基因组学和生物信息学方法揭示了在肝癌发生发展及转移过

Cell Metab:无需穿刺,粪便微生物有望检测早期脂肪肝和肝硬化!

非酒精性脂肪肝(NAFLD)是一种肝组织学改变与酒精性肝病相类似,但无过量饮酒史的临床病理综合征。该病最终可导致肝硬化和肝癌,但病症往往发展为晚期时才会被发现。并且,诊断还需要进行侵入性的肝穿刺活检。为了更早、更无创地检测NAFLD,加州大学圣地亚哥医科大学NAFLD研究中心,人类长寿研究所和J.Craig Venter研究所的研究人员发现,患者粪便样本或肠道菌群或许就可用于预测晚期NAFLD,精

Hepatology:郑晓峰教授团队揭示肝癌新抑癌基因及其作用机制

肝细胞癌(HCC)是肝癌最常见的形式,占全球癌症病人死亡率的第二位。其五年生存率仅为15%左右,这在很大程度上是由于缺乏有效的药物治疗。雷帕霉素靶蛋白(mTOR)是一个细胞生长、代谢的中央控制器。它也是公认的抗癌药物的主要靶点。mTOR 信号通路高度激活是肝癌发生的关键驱动因素之一。然而,因为 mTOR 上游基因 PIK3CA 和 PTEN 在肝癌中的突变率低,所以 mTOR 过度激活的机制仍然不

Baidu
map
Baidu
map
Baidu
map